This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Infliximab is associated with an increased risk of...
Journal

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Read time: 1 mins
Published:31st Jan 2019
Author: Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH et al.
Availability: Pay for access, or by subscription
Ref.:Br J Dermatol. 2019 Feb;180(2):329-337.
DOI:10.1111/bjd.17036
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)


Background:
Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections.

Objectives: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on non-biologic systemic therapies.

Methods: A prospective cohort study was performed using data from BADBIR. Infliximab was compared to non-biologic systemic therapies, inclusive of any exposure to methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A or hydroxycarbamide. Serious infections were those associated with hospitalisation; the use of intravenous antimicrobial therapy; and/or led to death. Propensity-score inverse probability treatment weights were used to adjust for potential confounding from a priori identified covariates. Cox proportional hazards models were calculated to obtain hazard ratios.

Results: 3843 participants were included for analysis up to October 2016. The incidence rates were significantly higher in the infliximab cohort (47.8 per 1000 person-years (95% confidence interval (CI) 35.7, 64.0) compared to 14.2 per 1000 person-years (95% CI 11.5, 17.4) in the non-biologic systemic cohort. Infliximab was associated with an overall increase in the risk of serious infection against non-biologics (adjusted hazard ratio (adjHR) 1.95, 95% CI 1.01, 3.75) and methotrexate only (adjHR 2.96, 95% CI 1.58, 5.57) and a higher risk of serious infection in the first 6 months of therapy (adjHR 3.49, 95% CI 1.14, 10.70).

Conclusions: Infliximab is associated with an increased risk of serious infections compared with non-biologic systemic therapies in patients with psoriasis in the United Kingdom and the Republic of Ireland.


Read abstract on library site    Access full article